The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...
Novavax (NASDAQ:NVAX) shares fell ~3% in the premarket on Thursday after the company issued a clarification on an analyst ...
One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...
The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...
Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...
Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively seeking out the lesser-known Novavax for their updated booster this fall.
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. Recently, Zacks.com users have been paying close ...
Novavax (NVAX) shares climbed 15% Wednesday after Jefferies released a bullish note on the company’s prospects after meeting ...
The mRNA-based supplier of vaccines profited from Covid-19 vaccine sales. As the years passed, Covid evolved. The weaker ...